Glycogen Storage Disease Type 5 Overview
Learn About Glycogen Storage Disease Type 5
Glycogen storage disease type V (also known as GSDV or McArdle disease) is an inherited disorder caused by an inability to break down a complex sugar called glycogen in muscle cells. A lack of glycogen breakdown interferes with the function of muscle cells.
Mutations in the PYGM gene cause GSDV. The PYGM gene provides instructions for making an enzyme called myophosphorylase. This enzyme is found only in muscle cells, where it breaks down glycogen into a simpler sugar called glucose-1-phosphate. Additional steps convert glucose-1-phosphate into glucose, a simple sugar that is the main energy source for most cells.
GSDV is a rare disorder; however, its prevalence is unknown. In the Dallas-Fort Worth area of Texas, where the prevalence of GSDV has been studied, the condition is estimated to affect 1 in 100,000 individuals.
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Alejandro Lucia practices in Madrid, Spain. Mr. Lucia is rated as an Elite expert by MediFind in the treatment of Glycogen Storage Disease Type 5. His top areas of expertise are Glycogen Storage Disease Type 5, Glycogen Storage Disease Type 7, Myoglobinuria Recurrent, Rhabdomyolysis, and Bone Marrow Transplant.
Alfredo Santalla practices in Sevilla, Spain. Mr. Santalla is rated as an Elite expert by MediFind in the treatment of Glycogen Storage Disease Type 5. His top areas of expertise are Glycogen Storage Disease Type 5, Myoglobinuria Recurrent, Rhabdomyolysis, and Phosphoglycerate Mutase Deficiency.
Gisela Gadea-Nogales practices in Badalona, Spain. Ms. Gadea-Nogales is rated as an Elite expert by MediFind in the treatment of Glycogen Storage Disease Type 5. Her top areas of expertise are Glycogen Storage Disease Type 5, Glycogen Storage Disease Type 7, Paramyotonia Congenita, Myotonic Dystrophy Type 2, and Thymectomy.
Published Date: June 01, 2014
Published By: National Institutes of Health